Palmar plantar erythrodysesthesia historical perspective

	Palmar plantar erythrodysesthesia Microchapters
Home
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Palmar plantar erythrodysesthesia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Palmar plantar erythrodysesthesia historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Palmar plantar erythrodysesthesia historical perspective
CDC on Palmar plantar erythrodysesthesia historical perspective
Palmar plantar erythrodysesthesia historical perspective in the news
Blogs on Palmar plantar erythrodysesthesia historical perspective
Directions to Hospitals Treating Palmar plantar erythrodysesthesia
Risk calculators and risk factors for Palmar plantar erythrodysesthesia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D.

Overview

In 1974, Zuehlke was the first to describe PPE in a patient receiving mitotane for hypernephroma.^[1]

↑ J. E. Fitzpatrick (1993). "The cutaneous histopathology of chemotherapeutic reactions". Journal of cutaneous pathology. 20 (1): 1–14. PMID 8468414. Unknown parameter |month= ignored (help)